BioNTech Results Presentation Deck

Autogene cevum eran (BNT122): First Patient Dosed in Phase 2 Clinical Trial in Adjuvant Colorectal Cancer Randomized, Phase 2 trial evaluating autogene cevumeran* in the adjuvant treatment of circulating tumor DNA positive, surgically resected Stage II (high risk)/Stage III colorectal cancer ● Colorectal cancer is second deadliest cancer worldwide ¹, 5 year OS in regional disease is 71% ² SoC in Stage II (high risk) and Stage III CRC after removal of the primary tumor and adjuvant chemotherapy is watchful waiting ctDNA is a marker for minimal residual disease and thus can identify patients at high risk of disease recurrence³,4 In ctDNA-positive, Stage 2 (high risk) and Stage 3 CRC post AdCTx, duration of disease free survival is 6 months5 Challenge in Adjuvant Setting in Stage 2 (high risk) and Stage 3 Colorectal Cancer: Residual cancer cells may remain. Stage II (high risk) and Stage III colorectal cancer 20 Surgery CT scan Adjuvant chemo given to all patients OS, Overall Survival; CRC, Colorectal Cancer; SoC, Standard of Care; ctDNA, circulating tumor DNA; AdCTx, adjuvant chemotherapy No Residual Disease Microscopic Residual Disease ¹WHO factsheet on cancer. 2018; 2Seer database; ³Fan et al, PLoS One 2017; 4Loupakis et al. 2021, JCO Precision Oncology; "Reinert et al., JAMA Oncology, 2019 *Autogene cevumeran is partnered with Genentech 50% Cured by surgery alone 20% Cured by chemo on top of surgery 30% Recur despite surgery + chemo BIONTECH

View entire presentation